<i>Ipr</i> T cells vaccinate against lupus in MRL/<i>lpr</i> mice
Article 1992 en
Authors
IA
Ignacio Moreno de Alborán
JG
José C. Gutierrez
JG
Jose Angel Gonzalo
Abstract
1 min read
Abstract MRL/MP‐ lpr/lpr mice are homozygous for the lpr mutation that results in the accumulation of phenotypically abnormal cells (CD3 + CD4 + CD8 − ) in all lymphoid issues. Although no major abnormalities in the T cell receptor repertoire expressed by such lpr cells have been reported, the lpr mutation is a major disease‐accelerating factor. Finally, intravenous administration of irradiated lpr cells recovered from the hyperplastic lymph nodes of adult diseased animals to young MRL/Mp‐ lpr/lpr mice resulted in a highly significant amelioration of disease parameters. This “T cell vaccination” approach resulted in a selective depletion of cells expressing products of the V β 8.2 subfamily among lymph node T cells, in addition to eliciting a surge in peripheral T cells capable of conferring disease protection in adoptive transfer experiments. Thus, a strategy aimed at specifically reducing the frequency of lpr cells proved successful in mitigating the autoimmune process. These findings add to the involvement of lpr cells in the autoimmune process and constitute the first report that T cell vaccination may be beneficial to a spontaneously occurring autoimmune disease.
Ramanjaneyulu Allam, Rahul D. Pawar, Onkar P. Kulkarni, Veit Hornung, Günter Hartmann, Stephan Segerer, Akira Shizuo, Stefan Endres, Hans‐Joachim Anders
Maria Dall’Era, Mariela Pauli, Kelly A. Remedios, Keyon Taravati, Priscila M. Sandova, Amy Putnam, Angela Lares, Anna Haemel, Qizhi Tang, Marc Hellerstein, Marc Fitch, James McNamara, Beverly Welch, Jeffrey A. Bluestone, David Wofsy, Michael D. Rosenblum
Discussion(0)
No comments yet. Be the first to comment.